FDA observations, leadership change keep Sun Pharma stock in spotlight on Monday
The US Food and Drug Administration (USFDA) issued a Form-483 with eight observations concerning manufacturing practices at Sun Pharma's Halol facility in Gujarat. While the observations do not constitute regulatory action, they point to areas requiring corrective measures to meet FDA compliance standards. Sun Pharma has acknowledged the observations and committed to addressing them promptly.
The inspection, conducted between June 2 and June 13, 2025, is especially significant as the Halol plant has been under an import alert since December 2022 due to previous regulatory violations.
In a parallel development, the company announced the elevation of Kirti Ganorkar to the role of Managing Director, effective September 1, 2025. Ganorkar, who has headed Sun Pharma's India business since 2019, will take over full operational responsibilities, with all functions reporting directly to him. Founder Dilip Shanghvi will continue as Executive Chairman of the Board, ensuring strategic continuity.
In light of these developments, investors are expected to closely monitor the company's stock performance in the coming days. Market analysts say the resolution of USFDA concerns at Halol and the smooth execution of the leadership transition will be key to shaping investor sentiment and the company's near-term outlook.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 hours ago
- Time of India
Glenmark, Alembic Pharma, Sun Pharma recall products in US: USFDA
Drug makers Glenmark , Alembic Pharmaceuticals and Sun Pharma are recalling products in the US due to manufacturing issues, according to the US health regulator. Independence Day 2025 Modi signals new push for tech independence with local chips Before Trump, British used tariffs to kill Indian textile Bank of Azad Hind: When Netaji Subhas Chandra Bose gave India its own currency Mumbai-based Glenmark is recalling two products in the market, the US Food and Drug Administration ( USFDA ) said in its latest Enforcement Report. Glenmark Pharmaceuticals Inc, USA, a subsidiary of the company, is recalling Carvedilol tablets, used to treat heart failure, hypertension, and heart attack, in multiple strengths. The New Jersey-based firm is recalling 55,560 units of the affected lot due to "presence of a nitrosamine, N-Nitroso Carvedilol impurity above the current acceptable intake level," the USFDA stated. The company is also recalling 17,496 bottles of Carvedilol tablets as "results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm," it added. Live Events Glenmark initiated the Class II recall in August this year. USFDA said the company is also recalling 22,656 bottles of Theophylline extended-release tablets (400 mg) for failed dissolution specifications. Alembic Pharmaceuticals is recalling 9,492 bottles of Doxepin Hydrochloride capsules, used in the treatment of insomnia, the US health regulator stated. The Class II recall is due to the "Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit," it said. The company initiated the recall on July 25 this year. New Jersey-based Sun Pharmaceutical Industries Inc is recalling 11,328 bottles of Spironolactone Tablets, used to treat high blood pressure, due to "Presence of foreign substance: identified as aluminum," the regulator said. The company commenced the Class II recall on August 5. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.
Economic Times
9 hours ago
- Economic Times
Alembic gets USFDA nod for generic drug for skin condition
Synopsis Alembic Pharmaceuticals has secured USFDA approval for its generic Tretinoin Cream USP (0.025%), a treatment for acne vulgaris. This ANDA is therapeutically equivalent to Bausch Health US, LLC's Retin-A Cream. The market size for Tretinoin cream USP (0.025%) is estimated at USD 94 million for the twelve months ending June 2025. Agencies Alembic (Representative image) Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic medication to treat acne vulgaris in the US market. The company has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Tretinoin Cream USP (0.025 per cent), the drug maker said in a statement. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Retin-A Cream, 0.025 pr cent, of Bausch Health US, LLC, it added. Tretinoin cream is indicated for topical application in the treatment of acne vulgaris. According to IQVIA, Tretinoin cream USP, 0.025 per cent, has an estimated market size of USD 94 million for the twelve months ending June 2025. Shares of the company were trading 1.03 per cent up at Rs 968.10 apiece on BSE.
Time of India
14 hours ago
- Time of India
Sun Pharma Share Price Live Updates: Sun Pharma's three-month performance shows negative returns
18 Aug 2025 | 09:03:45 AM IST Discover the Sun Pharma Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent stock. Keep track of Sun Pharma with the latest details, including: Last traded price 1638.6, Market capitalization: 393826.84, Volume: 2429, Price-to-earnings ratio 37.97, Earnings per share 43.23. Our comprehensive coverage combines fundamental and technical indicators to provide you with a comprehensive view of Sun Pharma's performance. Stay informed about breaking news that can sway Sun Pharma's trajectory in the market. With our expert insights and stock recommendations, make well-informed financial decisions. Join us on this journey as we explore the exciting potential of Sun Pharma. The data points are updated as on 09:03:44 AM IST, 18 Aug 2025 Show more
